These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34380538)

  • 1. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
    Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
    Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
    Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
    Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial.
    Lodise T; Yang J; Puzniak LA; Dillon R; Kollef M
    Infect Dis Ther; 2020 Dec; 9(4):953-966. PubMed ID: 32996064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
    Martin-Loeches I; Shorr AF; Wunderink RG; Kollef MH; Timsit JF; Yu B; Huntington JA; Jensen E; Bruno CJ
    Ann Intensive Care; 2023 Feb; 13(1):8. PubMed ID: 36773112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
    Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
    Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
    Paterson DL; Bassetti M; Motyl M; Johnson MG; Castanheira M; Jensen EH; Huntington JA; Yu B; Wolf DJ; Bruno CJ
    J Antimicrob Chemother; 2022 Aug; 77(9):2522-2531. PubMed ID: 35781341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
    Huntington JA; Yu B; Li L; Jensen E; Bruno C; Boakye M; Zhang Z; Gao W; Feng HP; Rhee E
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
    Shorr AF; Bruno CJ; Zhang Z; Jensen E; Gao W; Feng HP; Huntington JA; Yu B; Rhee EG; De Anda C; Basu S; Kollef MH
    Crit Care; 2021 Oct; 25(1):354. PubMed ID: 34600585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M
    Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
    Martin-Loeches I; Timsit JF; Kollef MH; Wunderink RG; Shime N; Nováček M; Kivistik Ü; Réa-Neto Á; Bruno CJ; Huntington JA; Lin G; Jensen EH; Motyl M; Yu B; Gates D; Butterton JR; Rhee EG
    J Antimicrob Chemother; 2022 Mar; 77(4):1166-1177. PubMed ID: 35022730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Naik J; Puzniak L; Critchlow S; Elsea D; Dillon RJ; Yang J
    Infect Dis Ther; 2021 Jun; 10(2):939-954. PubMed ID: 33837518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
    Gao W; Passarell J; Patel YT; Zhang Z; Lin G; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda CS; Feng HP
    Antimicrob Agents Chemother; 2022 May; 66(5):e0139921. PubMed ID: 35471040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan.
    Takaya R; Mori N; Saito E; Ohde S
    BMC Health Serv Res; 2024 Mar; 24(1):389. PubMed ID: 38549158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
    Martin-Loeches I; Bruno CJ; DeRyke CA
    Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Characterization of Baseline
    Castanheira M; Johnson MG; Yu B; Huntington JA; Carmelitano P; Bruno C; Rhee EG; Motyl M
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
    J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane-tazobactam in nosocomial pneumonia.
    Candel FJ; González Del Castillo J; Julián Jiménez A; Matesanz M
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):35-39. PubMed ID: 35488823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
    Feng HP; Patel YT; Zhang Z; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda C; Gao W
    J Clin Pharmacol; 2023 Feb; 63(2):166-171. PubMed ID: 36046982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia.
    Los-Arcos I; Burgos J; Falcó V; Almirante B
    Expert Opin Pharmacother; 2020 Jun; 21(9):1005-1013. PubMed ID: 32212866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.